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Introduction: The main aim of this study is to evaluate potential human stem cells, such as dental pulp stem cells
and amniotic fluid stem cells, combined with collagen scaffold to reconstruct critical-size cranial bone defects in an
animal model.
Methods: We performed two symmetric full-thickness cranial defects on each parietal region of rats and we
replenished them with collagen scaffolds with or without stem cells already seeded into and addressed towards
osteogenic lineage in vitro. After 4 and 8 weeks, cranial tissue samples were taken for histological and
immunofluorescence analysis.
Results: We observed a new bone formation in all of the samples but the most relevant differences in defect
correction were shown by stem cell–collagen samples 4 weeks after implant, suggesting a faster regeneration
ability of the combined constructs. The presence of human cells in the newly formed bone was confirmed by
confocal analysis with an antibody directed to a human mitochondrial protein. Furthermore, human cells were
found to be an essential part of new vessel formation in the scaffold.
Conclusion: These data confirmed the strong potential of bioengineered constructs of stem cell–collagen scaffold
for correcting large cranial defects in an animal model and highlighting the role of stem cells in neovascularization
during skeletal defect reconstruction.
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Over 2 million bone replacement procedures are
performed every year worldwide requiring the use of
bone graft materials. This makes bone second only to
blood on the list of transplanted materials. With demand
escalating and increasing limitations with traditional
bone graft supply, techniques are being developed to
provide alternatives with properties suitable for clinical
use [1-4].* Correspondence: tullia.maraldi@unimore.it
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reproduction in any medium, provided the orA critical-size bone defect will not heal spontaneously
and tissue engineering strategies are a very promising
option [5]. For this strategy, therapeutic scaffolds have
been developed from various classes of natural materials
including collagen, fibroin [6] and hyaluronic acid-based
hydrogel [7]. Indeed, cell-free scaffolds as tissue graft
substitutes have been used in the human clinical setting
since Yannas and colleagues developed the collagen
glycosaminoglycan scaffold for skin grafting [8,9].
Among the natural-derived polymers, collagen – the
most abundant protein in the body and the major com-
ponent of the extracellular matrix – is regarded as one
of the most useful biomaterials for growth factor delivery
owing to its excellent biocompatibility and safety [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scaffolds undergo deformation leading to an implant
compression within the defect or are even displaced be-
yond the borders of the defect site [11]. However, most
of materials possessing the needed mechanical forces are
not optimal for cell growth and differentiation [5].
The potential of cell-free scaffolds to be used as an
off-the-shelf product presents an ideal clinical solution
to the limitations of traditional bone graft; however, cell-
free scaffolds are inadequate for large bone defects and
the principal strategies of bone tissue engineering sug-
gest the use of cells seeded onto scaffolds prior to
implantation.
Recent investigations have focused on the use of stem
cells instead of mature differentiated cell types due to
their expansion potential and ease of access. In particu-
lar, mesenchymal stem cells have shown promising re-
sults in a number of tissue engineering areas; for
example, tendon [12,13], cartilage [14], fat [15] and bone
[15-17]. Previously, we have demonstrated the osteo-
genic potential of human dental pulp stem cells (DPSCs)
and amniotic fluid stem cells (AFSCs) in vitro and
in vivo in an ectopic model [18,19]. Human DPSCs and
AFSCs both present the advantage of easy recruitment
without ethical problems; in fact, they can be easily iso-
lated and expanded in culture showing in vitro and
in vivo multipotential or pluripotential plasticity.
Some of the fundamental features of biomaterials
thought to be important for effective bone regeneration
include: a biochemical composition and structure that
supports osteogenic cell responses; appropriate kinetics of
biodegradability, without any release of toxic byproducts;
and a highly interconnected porous network that allows
for proper tissue in growth and vascularization of the bio-
material [20]. Vascularization of the biomaterial is there-
fore an essential step in tissue healing, as this process
provides the nutrients and oxygen needed for bone cells
to survive, while facilitating removal of waste products
from cell metabolism, avoiding the onset of a necrosis
process [21-24].
We have already investigated the stem cells/scaffold
construct potential in osteo regeneration in vivo, focus-
ing on the analysis of new scaffold applications [18,25].
Here we present an evaluation of the vascularization
capability role of human stem cells, derived from alter-
native sources, during bone reconstruction in animal
bone defects. For this purpose we decided to employ a
collagen-based scaffold since it is already used in clinical
practice and it is suitable in bone regeneration for prop-
erties of osteoinductivity and biocompatibility. We chose
a cranial defect in order to exclude the lack of stability
problem of collagen scaffold.
The specific aims of this study were therefore: to com-
pare the ability of collagen and tissue-engineeredconstructs seeded with human stem cells, to heal
critical-size bone defects using an established rat cranial
defect in vivo model; and to determine the relationship
between the neovascularization and the overall defect
healing.
Healing rates were assessed by measuring new bone
formation within the defect using histomorphometric
techniques. Immunohistochemistry was carried out to
analyze the differentiation potential of the tissue-
engineered constructs and the cell-free scaffolds.
Materials and methods
Cell culture and seeding
Supernumerary amniocentesis samples were provided by
the Laboratorio di Genetica, Ospedale Santa Maria
Nuova (Reggio Emilia, Italy). All samples were collected
with informed consent of the patients according to Italian
law and ethical committee guidelines.
AFSCs were isolated as previously described by De
Coppi and colleagues [26]. Human amniocentesis cultures
were harvested by trypsinization, and subjected to c-Kit
immunoselection by MACS Technology (Miltenyi Biotec,
Cologne, Germay). Human AFSCs were subcultured rou-
tinely at 1:6 dilution and were not allowed to expand
beyond the 70% of confluence.
Human DPSCs were isolated as previously described
by Riccio and colleagues [27]. Briefly, DPSCs were
obtained by magnetic cell sorting using MACS Technol-
ogy by three successive sortings performed using specific
antibodies against: CD34, a marker of stromal and
hemopoietic pluripotent stem cells; c-Kit, the tirosin-
kinase receptor of stem cells factor; and STRO-1, a stro-
mal stem cell surface marker.
AFSCs and DPSCs were grown in culture medium of
αMEM supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin and 100 μg/ml strepto-
mycin (all Invitrogen, Carlsbad, CA, USA).
Discs of height 1.5 mm and diameter 13 mm were cut
from collagen scaffolds (sponges of horse-derived colla-
gen – Condress, Istituto Gentilini, Pisa, Italy) and placed
in 24-well tissue culture plates. All scaffolds were then
washed twice with culture medium (1 hour for each
rinse). Cells, at the third passage, were seeded on each scaf-
fold at density of 1,500 cells/mm3 and cultured for 24
hours with 2 ml culture medium. After 24 hours the cul-
ture medium was changed for osteogenic medium (culture
medium supplemented with 100 nM dexamethasone, 10
mM β-glycerophosphate, 50 μg/ml ascorbic acid-2-phos-
phate; Sigma-Aldrich, St Louis, MO, USA). Cell/scaffold
cultures were then maintained in osteogenic medium for 1
week in an incubator at 37°C with 5% CO2 (medium
changed twice). Some samples were stained with
6-carboxyfluorescein diacetate (Sigma-Aldrich) to test the
viability of seeded cells.
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For implantation, CD® IG5 male rats with age ranging
between 12 and 14 weeks (Charles River Laboratories,
Lecco, Italy) were used in the study.
To evaluate the potential of the DPSCs and AFSCs to
reconstruct large cranial defects, we performed two sym-
metric full-thickness cranial defects of 5 mm × 8 mm on
each parietal region of 30 animals (see Additional file 1)
[18]. The animals were anesthetized with an intraperito-
neal injection (0.2 ml/100 g body weight) of ketamine
hydrochloride (5%). A midline skin incision was
performed from the nose-frontal area to the external
occipital protuberance.
The skin and underlying tissues, including the perios-
teum, were reflected laterally to expose the full extent of
the calvaria. The cranial defect was performed with a
drill with a micromotor under constant irrigation with
sterile physiological solution to prevent overheating of
the bone. The underlying dura mater was undisturbed.
One scaffold 5 mm × 8 mm × 1.5 mm size was im-
planted into each cranial defect and adapted to fill the
entire defect area. Each animal received two equal con-
structs. After the scaffold implantation, the incisions
were sutured with prolene 4–0 sutures (Ethicon, Roma,
Italy). Animals were immunocompromised using cyclo-
sporine A at a dosage of 15 mg/kg body weight, admin-
istered 4 hours before transplantation and then daily for
2 weeks. During the last weeks the daily dosage was
reduced gradually up to 6 mg/kg body weight.
The rats were sacrificed 4 and 8 weeks later and the
calvariae were rapidly explanted and fixed in 4% parafor-
maldehyde in PBS for 3 hours. All animal procedures
were performed according to the guidelines approved on
19 October 2010 by the Committee of Use and Care of
Laboratory Animals of the University of Modena e Reggio
Emilia.
All experiments were carried out according to the Bio-
ethical Committee of the Italian National Institute of
Health. Animal care, maintenance and surgery were
conducted in accordance with Italian Law (D.L. No. 116/
1992) and European legislation (ECC No. 86/609).
Radiography
Explanted calvariae samples were radiographed by a
Kodak RVG Digital Radiography System (FORB, Torino,
Italy).
Histology
Histological sections were stained with Alizarin Red
staining for light microscopic observation. Fixed samples
were decalcified in 0.5 M ethylenediamine tetraacetic
acid, pH 8.3. Parietal bones were then rinsed in PBS,
dehydrated with graded ethanol, diaphanized and em-
bedded in paraffin. Transversal serial sections (10 μmthick) were cut through the midline of the implant area.
Routine H & E staining was performed to analyze mor-
phological details.
Immunohistochemistry was performed using mouse
anti-human mitochondrial protein (Millipore, Billerica,
MA, USA). Endogenous peroxidase activity was
quenched by first incubating sections in 10% methanol
and 3% H2O2, followed by three washes in Tris-buffered
saline (pH 7.4), and incubation for 1 hour in 3% BSA in
Tris-buffered saline with 0.2% Triton X-100. Sections
were incubated overnight in the primary antibody in
Tris-buffered saline with 0.2% Triton X-100. Following
three 10-minute washes, tissue sections were incubated for
1 hour in peroxidase-labeled anti-mouse (Amersham GE
Healthcare, Freiburg, Germany). Following another three
washes, staining was visualized using diaminobenzidine
(2 mg/ml) and H2O2 (0.3 μl/ml). Sections were then
stained with Harris hematoxylin. Images of histological
samples were obtained by a Zeiss Axiophot microscope
equipped with polarizer filters and with a Nikon DS-5Mc
CCD color camera (Nikon Instruments, Japan).
Confocal microscopy
Histological sections were processed as previously de-
scribed by Riccio and colleagues [27]. Mouse anti-
human mitochondrial protein (diluted 1:100; Millipore),
rabbit anti-von Willebrand (diluted 1:50; Sigma Aldrich),
and osteocalcin (diluted 1:50; Millipore) in PBS containing
3% BSA for 1 hour at room temperature were used as pri-
mary antibodies. Secondary antibody was diluted 1:200 in
PBS containing 3% BSA (goat anti-mouse Alexa 647, goat
anti-rabbit Alexa 546). After washing in PBS, samples
were stained with 1 μg/ml 4′,6-diamidino-2-phenylindole
in H2O for 1 minute and then mounted with anti-fading
medium (0.21 M 1,4-diazabicyclo[2.2.2]octane and 90%
glycerol in 0.02 M Tris, pH 8.0). Negative controls
consisted of samples not incubated with the primary
antibody.
Confocal imaging was performed on a Nikon A1
(Nikon Instruments, Japan) confocal laser scanning
microscope as described previously [28]. Spectral ana-
lysis was carried out to exclude overlapping between two
signals or the influence of autofluorescence background
on the fluorochrome signals. The confocal serial sections
were processed with ImageJ software to obtain three-
dimensional projections, as described previously [18].
The image rendering was performed by Adobe
Photoshop software (Adobe Systems Software, Ireland).
Statistical analysis
In vitro experiments were performed in triplicate. For
in vivo experiments each treatment was performed twice
(two cranial defects) in five animals. For quantitative
comparisons, values were reported as mean ± standard
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To test the significance of observed differences between
the study groups, analysis of variance with post-hoc
Bonferroni correction was applied. P <0.05 was consid-
ered statistically significant.
Results
To study the bone-forming ability of AFSCs and DPSCs
on collagen scaffolds, a critical-size bone defect was
obtained by a full-thickness dissection removing both
the internal and external tables of compact bone and the
trabecular diploë constituting the parietal skeletal seg-
ment. The stem cell–scaffold constructs were induced in
osteogenic medium for 7 days, in order to have a cell
population committed to osteogenic differentiation yet able
to proliferate. After 1 week of osteogenic medium exposure,
expression of the typical markers for osteodifferentiation,
such as osteocalcin, osteopontin and osterix, is not different
from nonexposed AFSCs and DPSCs [19,27]. Tests
performed with the 6-carboxyfluorescein diacetate probe
demonstrated that, 7 days after the cell seeding into the
scaffold before implant, scaffolds are colonized by viable
cells. In order to check the cell presence inside the scaffold,
confocal analysis of 100 μm collagen sponge thickness was
performed and is shown in Figure 1. Further, both cell types
are present and homogeneously distributed within the
micro-cavities delineated by the scaffold architecture and
no difference in the cell density was observed.
Constructs were than implanted into a critical-size
parietal defect for up to 8 weeks. None of the animals
died of infection or any other complication.
Radiological analysis
Radiography scans of ex vivo bone explants demonstrate
qualitatively and quantitatively mineralized tissue levels
in the defect (Figure 2).Figure 1 Microscopic analysis of dental pulp and amniotic fluid stem
stained cells present in (A) dental pulp stem cell–collagen and (B) amniotic
analyzed by in vivo confocal microscopy. Confocal images of cells (green) w
scaffolds (gray). Scale bar = 20 μM.Most notably, the empty control group remains largely
void of mineralized tissue (Figure 2A, right) and the un-
seeded collagen group shows progressive infilling with
mineralized tissue (Figure 2B) showing low to moderate
rates of bone growth in the defect. After 4 weeks, AFSC-
seeded samples show the best bone formation compared
with the other groups. Both AFSC and DPSC seed scaf-
fold groups (Figure 2C,D) showed almost complete
bridging of the defect by 8 weeks. This suggests a higher
mineralized tissue volume in the defect treated with the
cell-seeded scaffolds compared with the cell-free colla-
gen sponge.
Qualitative histology
To evaluate the parietal bone reconstructing process by
histological analysis, serial sections of the middle line of
the parietal bone defect containing the implants were
stained with H & E. Samples were then observed by
white field and polarized light microscopy.
Figure 3 presents representative photomicrographs of
engineered osseous grafts in vivo. The presence of vessels
in the scaffold area indicates that all implanted constructs
have been successfully vascularized in unmineralized
tissue (as indicated by arrows in Figure 3, collagen,
collagen+DPSC, collagen+AFSC F) and in mineralized
tissues in (as indicated by arrows in Figure 3, collagen
+DPSC, collagen+AFSC E).
The bone defects not treated with implant, after 4
weeks, appear filled with structurally and morphologic-
ally organized fibrous tissue consistent with failure to
heal the bone defect (shown in [18]), demonstrating the
critical size of the defect. After 4 weeks, in the collagen
scaffold alone implant, fibrous tissue extends from the
defect margin (Figure 3, collagen A) with a few small
areas of new bone formation visible immediately adja-
cent to the host bone (to the left of the dotted line incells cultured in collagen scaffolds. 6-Carboxyfluorescein diacetate-
fluid stem cell–collagen constructs after 7 days of culture were
ere superimposed to differential interference contrast images of
Figure 2 Radiological analysis of rat calvariae dissected 4 or 8
weeks after surgery. Images are representative of (A) intact bone
(left panel) and the bone healing in the cranial defects (right panel),
(B) scaffolds alone, and scaffold seeded with (C) dental pulp stem
cells or (D) amniotic fluid stem cells.
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ation. However, the sample presented mineralized matrix
and calcium deposition, as noted by Alizarin staining
(Figure 3, collagen C). Some areas of unfilled defect were
still occupied by remnant of the scaffold implanted at
surgery (Figure 3, collagen A,B). A rim of osteoblasts
exhibited a dense arrangement at the inner edge of the
newly formed woven bone (Figure 3 collagen B), with
osteoid forming in advance of this. After 8 weeks of im-
plant, collagen scaffold filled defects did exhibit much more
complete signs of healing (as demonstrated in Figure 3,
collagen D,E,F; see Additional file 2). However, the bone re-
generation occurs prevalently in the scaffold layers directly
in contact with the outer surface of the dura mater.
The presence of human stem cells dramatically improves
the restoration power of collagen scaffold (Figure 3, colla-
gen+DPSC, collagen+AFSC), as shown before by radio-
graph analysis. With both stem cell types, we can observe
that the defect is partially recovered by newly formed bone
tissue that appears discontinuous and thinner than pre-
existing bone after 4 weeks. In fact, the margins of newly
formed bone were unconnected with the pre-existingbone while, between them, connective tissue was
present (Figure 3, collagen+DPSC A, collagen+AFSC A).
In particular, the AFSC sample showed a better recovering
performance (Figure 3, collagen+AFSC A) compared with
the DPSC sample (Figure 3, collagen+DPSC A). Moreover,
Alizarin red analysis confirmed the characteristics of bone
regeneration inside the defects (Figure 3, collagen+DPSC
C, collagen+AFSC C). After 8 weeks, however, the bone
defects appear almost completely filled in both bone
layers (Figure 3, collagen+DPSC D, collagen+AFSC D; see
Additional file 2).
The presence of a vast network of vessels is clearly vis-
ible in the not yet mineralized construct area (Figure 3,
collagen F, collagen+DPSC F, collagen+AFSC F).
Quantitative histomorphometry
Quantitative histomorphometry was carried out to deter-
mine the levels of healing in the different groups after 4
weeks. Quantitative values of thickness (Figure 4A) were
obtained by measuring at 10 different points the thick-
ness of the new bone for each sample and normalizing
the average obtained to the respective thickness of
squamosal suture (suture connecting the temporal bones
to the parietal bones) (TSO). The average of all 10 sam-
ples is shown in Figure 4A. We also compared the ratio
obtained between the regenerated bone area value (AR)
and the pre-existing parietal area value (AO). The nor-
mal area (AO) of each sample was calculated considering
the area value of the nonoperated sample (AC) and the
thickness of its squamosal suture (TSC). For each sam-
ples, the pre-existing area value (before the operation,
AO) is obtained through the following ratio: TSC:TSO =
AC:AO.
The cell-free group showed mineralized tissue levels in
the defect of around 30%, and the cell-seeded groups
were significantly higher. In particular, we also observed
a significant difference between AFSC and DPSC area
reconstruction, suggesting that the AFSC/collagen con-
struct has the highest potential.
In parallel we carried out quantitative counting of ves-
sels present in the collagen scaffold not yet modified in
mineralized tissue, in order to compare the three differ-
ent groups also for their new vascularization potential.
In fact, the number of vessels inside the new bone does
not differ among the three types of constructs (data not
shown). However, as shown in Figure 4B, cell-seeded
groups clearly present a higher number of vessels, both
capillary and bigger vessels (a capillary being considered
a vessel with diameter <20 μm). The collagen group
demonstrated tiny areas of new vessel formation at the
defect margin, reaching 4 ± 2.5 in the defect area. The
cell-seeded groups demonstrated an ability to stimulate
vascularization, since the ratio between the samples with
cells and those without is >1.5 for both cell types and
Figure 3 Comparative histologic analysis of cranial defect reconstruction 4 and 8 weeks post surgery. Comparative histologic analysis of
cranial defect reconstruction by collagen, collagen + dental pulp stem cell (DPSC) or collagen + amniotic fluid stem cell (AFSC) constructs 4 and
8 weeks post surgery. (A) H & E staining of cranial defects closed with constructs 4 weeks after implant (magnified in (B) and (C) staining for
Alizarin red. (D) Representative images showing samples 8 weeks after implant (magnified in (E), (F). Dotted line defines (left) the host bone and
(right) the new bone. Arrowheads indicate vessels. Scale bar = 100 μM. ft, fibrous tissue; or, osteoblasts; os, osteoid.
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Figure 4 Quantitative histomorphometry for histologic analysis
of cranial defect reconstruction by collagen constructs 4 weeks
post-surgery. (A) Percentage of reconstructed normal thickness and
area of parietal bone in the three different groups. (B) Average
number of vessels present in 0.12 mm of implant. Values, calculated
on three slices of each of the 10 specimens for group, are expressed
as mean ± standard deviation. *P ≤0.05, **P ≤0.01, ***P ≤0.001
versus collagen group; °P ≤0.05 versus collagen+DPSC group. AFSC,
amniotic fluid stem cell; DPSC, dental pulp stem cell.
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clearly shows the presence of several arterioles with
diameter around 50 μm in samples seeded with DPSCs
and AFSCs. This suggests a possible connection between
a higher amount of vessels and mineralized tissue in the
defect treated with the cell scaffolds compared with the
empty defect and the collagen groups.
Immunohistochemistry
The aim of this part of the study was to establish the cell
nature of the osteo and vascular tissue in engineered
constructs. Based on our recent work [18], cells insidethe new bone were still of human origin and not from
the host, after 4 weeks of implants. We demonstrate this
issue by four different approaches: RT-PCR analysis (see
Additional file 3), fluorescence hybridation in situ ana-
lysis (see Additional file 4), immunofluorescence experi-
ments investigating the presence of human nuclei (see
Additional file 5), and human mitochondria (reported
below). This was possible by staining the ex vivo speci-
mens for with anti-human mitochondria, that recognizes
only mitochondrial protein from human origin. Both im-
munohistochemistry (Figures 5C,D and 6A,B,C,D) and
immunofluorescence analyzed with a confocal micro-
scope (Figures 5E,F and 6E,F) demonstrate the presence
of human cells in cell–collagen implants.
In control samples (collagen alone; data shown in
Additional file 6) only 4′,6-diamidino-2-phenylindole
staining occurs, while human mitochondria are not de-
tectable. In Figure 6E,F the images of stem cell–scaffold
implants demonstrate that most cells are clearly labeled
by anti-human mitochondria antibody, indicating sur-
vival of the donor cells in vivo also after 8 weeks of im-
plant. In particular, Figure 6E,F shows that human cells
are present around and inside lamellar tissue in growth,
as indicated by arrows, representing the osteoblast
mineralization front and osteocytes included in the min-
eralized matrix.
Double staining with anti-human mitochondria and
anti-osteocalcin, produced by osteoblasts and therefore
used as a marker for the bone formation process, was
then performed. Figure 6G,H,I,J,K shows that cells of
human origin (stained in red in Figure 6G,H) are also
positive for osteocalcin (green signal in Figure 6I,K),
confirming the functionality of the osteo-differentiated
human stem cells in vivo.
The same approach demonstrates that all new vessels,
some of them indicated by arrows in the figures, are
completely surrounded by an endothelium composed of
cells from human origin (Figure 5C,D,E,F). In fact, cells
labeling anti-von Willebrand (Figure 5G,H), a protein
produced constitutively in the endothelium, are also
positive for human mitochondria (Figure 5I,K).
In fact the capability of DPSCs and AFSCs to differen-
tiate in vascular tissue in vitro both autonomously and
after vascular endothelial growth factor exposure has
already been demonstrated by several authors [29,30].Discussion
Bone is a dynamic, highly vascularized tissue with the
unique capacity to heal and to remodel without leaving a
scar [31]. Large bone defects, caused by trauma, tumor
resection, or infections, require implants to restore the
loss of function. Current treatments of large bone de-
fects are based on autogene or allogene bone grafts and
Figure 5 (See legend on next page.)
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Figure 5 Presence of human stem cells in vessels 8 weeks after surgery. H & E staining of cranial defects (A) closed with collagen + dental
pulp stem cells (DPSC) and (B) closed with collagen + amniotic fluid stem cells (AFSC). Scale bar = 100 μM. Diaminobenzidine staining of cranial
defects (C) closed with collagen + DPSC and (D) closed with collagen + AFSC. Scale bar = 100 μM. Confocal images of implants obtained 8
weeks after surgery. Double fluorescence signals from 4’,6-diamidino-2-phenylindole (DAPI; red) and anti-human mitochondria protein (green)
antibody images: (E) collagen colonized with DPSC, (F) collagen colonized with AFSC. Triple fluorescence signals from DAPI (blue) and anti-
human mitochondria protein (red) antibody images or DAPI (blue) and anti-von Willebrand (green) antibody images: (G), (I) collagen colonized
with DPSC, (H), (K) collagen colonized with AFSC. Scale bar = 50 μM.
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tions. Bone tissue engineering could provide an alterna-
tive to conventional treatments of fracture healing.
However, this approach requires a matrix to allow pro-
genitor cell delivery and support tissue invasion.
Bone defect repair is one of the major targets of tissue
engineering research [32]. Pre-seeding a biomaterial with
tissue-specific cells prior to implant is one method that
is being examined to speed up tissue regeneration [33].
However, one of the major problems after the implant-
ation of large biomaterials is the slow vascularization of
the material [34].
Vascularization is a key process in tissue engineering
and regeneration and represents one of the most import-
ant issues in the field of regenerative medicine. Thus,
several strategies to improve vascularization are cur-
rently under clinical evaluation.
In fact, approximately 10% of fractures are slow or
nonhealing [35] and may be characterized by poor
vascularization and a resulting hypoxic local microenvir-
onment [36]. The absence of a sufficient vasculature im-
pairs native healing processes by limiting the availability
of nutrients to resident progenitor cells and infusion of
inductive factors from the systemic circulation that pro-
mote healing. The consequences of a low-oxygen envir-
onment on cells are unclear but may include enhanced
apoptosis, reduced proliferation, and inhibited differenti-
ation; all of which ultimately impact tissue repair.
Cell transplantation is a promising alternative to the
gold standard of autologous bone grafting to stimulate
bone repair. Human DPSCs or AFSCs are of great inter-
est in bone reconstruction, having demonstrated efficacy
in both preclinical and clinical models [18,19,37,38].
These stem cells can be easily isolated and expanded in
culture without ethical problems. Autologous transplant-
ation can be performed with both cell types. AFSCs can
be used in neonatal surgery to treat congenital malfor-
mation. DPSCs, available from puberty onwards, can be
used to heal pathologies occurring in adult life.
The objective of this study was to investigate whether
the application of collagen sponge scaffolds, combined
with expanded and osteogenic precultured human stem
cells, had an effect on vascularization and the osteogenic
potential of the scaffolds in vivo after implantation into
parietal bone defect of immunodeficient rats. We discusswhich combination of scaffold/cells shows the highest
potential for further investigations. Adequate porosity
and surface properties are recognized as important pa-
rameters in identifying scaffolds for tissue engineering.
Not fully interconnected and irregularly shaped pores
often lead to insufficient vascularization [39]. Depending
on the site of implantation, vascularization might be the
critical step for successful tissue engineering.
The collagen sponge scaffold, currently used in several
therapeutic practice, has been largely investigated in the
literature – some authors have reported that it is not ap-
propriate for successful new bone formation, because a
mineral matrix, or a bone morphogenetic protein-
expressing nonmineral matrix, or production of bone
morphogenetic protein-2 by genetically engineered cells
is also required [40]. However, our results contradict
these previous data, because the cell-free collagen
sponge showed an excellent healing bone process, espe-
cially at the longer time point. Our data therefore sup-
port the hypothesis that collagen membranes are a good
scaffold, facilitating cell adhesion and bone-forming cells
in the defect site.
However, our data show that cell-seeded scaffolds per-
form a better and faster bone reconstruction capability
than collagen alone. This improvement can be due to
both the osteogenic and the vascular differentiation po-
tential of DPSCs and AFSCs, even if AFSCs seems to
show a better result. Histological staining of human
mitochondria confirmed the presence of human stem
cells after 8 weeks of implantation in the new bone tis-
sue and also in vessels, creating the endothelium of the
new vessel network in the scaffold. A recent study
showed potential for AFSCs in bone regeneration and
angiogenesis in bone defects [41], while a demonstration
of the role of AFSCs in both the processes was lacking.
Our data demonstrate that human cells, present in the
graft after 2 months, are also expressing osteocalcin in-
side the new bone and von Willebrand factor around
vessels, being responsible for osteo and vascular forma-
tions. This may be due to the choice of implanting
AFSCs after 1 week of osteogenic differentiation in vitro.
In this condition osteogenic markers are not yet in-
creased, and therefore a subpopulation of undifferenti-
ated AFSCs could generate vessels, responding to local
environmental signals. Vascularization of cell-seeded
Figure 6 (See legend on next page.)
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Figure 6 Presence of human stem cells in the new bone 8 weeks after surgery. Diaminobenzidine staining of cranial defects (A), (C) closed
with collagen + dental pulp stem cells (DPSC) and (B), (D) closed with collagen + amniotic fluid stem cells (AFSC). Scale bar = 100 μM. Confocal
images of implants obtained 8 weeks after surgery. Double fluorescence signals from 4’,6-diamidino-2-phenylindole (DAPI; red) and anti-human
mitochondria protein (green) antibody images: (E) collagen colonized with DPSC, (F) collagen colonized with AFSC. Triple fluorescence signals
from DAPI (blue) and anti-human mitochondria protein (red) antibody images or DAPI (blue) and anti-osteocalcin (green) antibody images:
(G), (I) collagen colonized with DPSC, (H), (K) collagen colonized with AFSC. Scale bar = 50 μM.
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differentiation in the scaffold, because these cells need
oxygen to form osteoblasts.
The AFSC and DPSC populations employed here are
c-kit+ and ckit+-CD34+, respectively, being superficial
markers expressed in hematopoietic and vascular-
associated tissue [42].
Conclusion
Our findings support previous studies showing DPSC
and AFSC angiogenic capability [30,43] and indicate the
potential of these stem cells in several regenerative
medicine strategies, such as bone reconstruction, provid-
ing vascularization of the implant.
Additional files
Additional file 1: A table describing the three treatment groups of
implants.
Additional file 2: A figure showing H & E staining of serial
transversal sections (10 μm) of the whole cranial defect closed with
collagen or collagen + AFSC constructs 8 weeks post surgery. The
10 sections shown for each construct were obtained from the center
(top) to the end (bottom) for embedded samples. The images
demonstrate for both the shown samples that defects were completely
regenerated with bone tissue after 8 weeks of implant. The same pattern
was observed also for collagen + DPSC constructs (not shown).
Additional file 3: A figure showing human DNA detection in rat
bone samples: both samples of collagen seeded with DPSC or AFSC
react for human RNase P primers for DNA amplification in real-time
PCR. Right: reaction of a bone sample with a contamination of human
cells, so a sample with a small amount of human cells. Method:
Extraction Master pure complete (Epicenter); AB7000 platform (Applied
Biosystem); Human RNase P primers and kit of amplification from RNAse
P detection (Life Technologies, Paisley, UK).
Additional file 4: A figure showing DNA analysis with fluorescence
hybridization in situ: a probe for human X chromosome (Abbott
Molecular, Abbott Park, Illinois,USA) was used for checking the
nuclei form human origin inside implants (red spots into the
nuclei). We can observe the staining in part of the cells present inside
the new bone and vessels.
Additional file 5: A figure showing immunofluorescence for human
nuclei: anti-human nuclei (anti-nuclei antibody, clone 235–1 MAB1281,
species reactivity: human only; Millipore (Billerica, MA, USA) were used.
Anti-human nuclei (in red) co-localized with 4′,6-diamidino-2-
phenylindole staining in some cells present inside the implant,
demonstrating again the role of human cells in bone reconstruction. On
the other hand, outside the implant area, no reaction occurred.
Additional file 6: A figure showing negative control for reactions
with mouse anti-human mitochondria: image represents the
reaction with anti-human mitochondria in a sample of I Group,
without human cells seeded. The image shows that the green signal
(relative to h-mit) is very low, as a secondary antibody nonspecific signal.Abbreviations
AFSC: Amniotic fluid stem cell; BSA: Bovine serum albumin; DPSC: Dental
pulp stem cell; H & E: Hematoxylin and eosin; MEM: Modified Eagle’s
medium; PBS: Phosphate-buffered saline; PCR: Polymerase chain reaction;
RT: Reverse transcriptase.
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